ITGA5: A Potential Drug Target and Biomarker (G3678)

Target Name: ITGA5

NCBI ID: G3678

ITGA5

ITGA5: A Potential Drug Target and Biomarker

Introduction

The integrin subunit alpha 5 (ITGA5) is a protein that is expressed in various tissues throughout the body. It plays a crucial role in cell-cell adhesion and signaling, and is also involved in the development and progression of various diseases. As a result , ITGA5 has emerged as a promising drug target and biomarker for a variety of diseases.

Diseases andITGA5

One of the most significant ways that ITGA5 has been linked to disease is in the development of cancer. ITGA5 has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and prostate cancer cells. Additionally, ITGA5 has has also been linked to the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

ITGA5 as a Drug Target

The potential of ITGA5 as a drug target is based on its involvement in various signaling pathways that are associated with disease. For example, ITGA5 has been shown to be involved in the regulation of cell adhesion, which is a critical step in the development of cancer . Additionally, ITGA5 has been linked to the development of neurodegenerative diseases, which may be caused by the disruption of normal cellular signaling pathways.

ITGA5 as a Biomarker

In addition to its potential as a drug target, ITGA5 has also been shown to be a potential biomarker for several diseases. For example, ITGA5 has been shown to be involved in the development of various types of cancer, including breast, ovarian, and prostate cancer. Additionally, ITGA5 has been linked to the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

ITGA5 as a Potential therapeutic Approach

The potential of ITGA5 as a drug target and biomarker has led to a growing interest in the development of compounds that can inhibit its activity. Several studies have shown that ITGA5 can be inhibited by various small molecules, including inhibitors of tyrosine kinase signaling pathways, which are involved in the regulation of ITGA5 activity.

Conclusion

In conclusion, ITGA5 has emerged as a promising drug target and biomarker for a variety of diseases. Its involvement in cell-cell adhesion and signaling, as well as its link to the development of cancer and neurodegenerative diseases, makes it an attractive target for the development of new therapies. Further research is needed to fully understand the role of ITGA5 in disease and to develop effective treatments.

Protein Name: Integrin Subunit Alpha 5

Functions: Integrin alpha-5/beta-1 (ITGA5:ITGB1) is a receptor for fibronectin and fibrinogen. It recognizes the sequence R-G-D in its ligands. ITGA5:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGA5:ITGB1 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887, PubMed:17158881). ITGA5:ITGB1 is a receptor for IL1B and binding is essential for IL1B signaling (PubMed:29030430). ITGA5:ITGB3 is a receptor for soluble CD40LG and is required for CD40/CD40LG signaling (PubMed:31331973)

The "ITGA5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGA5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets